Braveheart Bio, Inc. Common Stock (BRVE) — Net Asset Quality Index
Braveheart Bio, Inc. Common Stock (BRVE) has a Net Asset Quality Index of -75.5% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $126.96 Million minus total liabilities of $222.86 Million yields net assets of $-95.91 Million. A higher index indicates a stronger, lower-leverage balance sheet. Explore debt repayment capacity of Braveheart Bio, Inc. Common Stock to assess how comfortably operating cash covers total debt obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Braveheart Bio, Inc. Common Stock Net Asset Quality Index Over Time (2025–2025)
This chart shows how Braveheart Bio, Inc. Common Stock's Net Asset Quality Index has evolved across 1 annual periods from 2025 to 2025. As of June 2026, the index stands at -75.5%, representing net assets of $-95.91 Million against total assets of $126.96 Million USD. See BRVE total equity for net asset value and shareholders' equity analysis.
Annual Net Asset Quality Index for Braveheart Bio, Inc. Common Stock (2025–2025)
The table below presents the year-by-year Net Asset Quality Index for Braveheart Bio, Inc. Common Stock from 2025 to 2025, covering 1 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see BRVE market cap overview.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -73.7% | $-65.87 Million | $89.35 Million | $155.22 Million | — |